Moreover, based on the REMAP-CAP international adaptive platform trial, designed to determine the best treatment strategies for patients with severe pneumonia, antiplatelet therapy (aspirin, and P2Y12  anatgonists, such as clopidogrel, ticagrelor or prasugrel) alongside a prophylactic dose of anticoagulation in severe COVID-19 patients also did not show clinical benefits but increased the risk of major bleeding [86]. Here, P2RY12 is linked to COVID-19.